---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-037728"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T07:48:57.720914+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novavax says COVID-19 vaccine BLA approvable; FDA requests additional clinical data as PMC

## Summary
- Believes BLA is approvable based on FDA conversations as of PDUFA date April 1 and through April 23.
- Received formal FDA information request for a post-marketing commitment (PMC) to generate additional clinical data.
- Intends to engage expeditiously with FDA to address the PMC and move to approval as soon as possible.

## SEC filing metadata
- accession: 0001104659-25-037728
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925037728/0001104659-25-037728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925037728/tm2512925d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-037728
- JSON: https://secwatch.observer/filing/0001104659-25-037728.json
- Plain text: https://secwatch.observer/filing/0001104659-25-037728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.